Gainers
- Psyence Biomedical PBM stock moved upwards by 68.1% to $1.0 during Thursday's after-market session. The market value of their outstanding shares is at $13.3 million.
- Kintara Therapeutics KTRA shares moved upwards by 15.67% to $0.32. The market value of their outstanding shares is at $17.5 million.
- Talphera TLPH shares rose 12.64% to $0.92. The market value of their outstanding shares is at $15.6 million.
- Helius Medical Tech HSDT shares moved upwards by 10.11% to $1.06. The market value of their outstanding shares is at $3.1 million.
- Clover Health Investments CLOV stock rose 9.72% to $1.13. The company's market cap stands at $561.0 million.
- Ensysce Biosciences ENSC shares increased by 8.77% to $0.6. The company's market cap stands at $4.5 million.
Losers
- Kineta KA stock fell 8.1% to $0.59 during Thursday's after-market session. The company's market cap stands at $7.2 million.
- Clene CLNN shares fell 4.99% to $0.37. The company's market cap stands at $47.7 million.
- Alzamend Neuro ALZN shares declined by 4.86% to $0.39. The market value of their outstanding shares is at $2.8 million.
- SenesTech SNES stock fell 4.28% to $0.59. The market value of their outstanding shares is at $3.0 million.
- Portage Biotech PRTG stock decreased by 4.26% to $0.27. The market value of their outstanding shares is at $5.3 million.
- Trevena TRVN shares fell 4.07% to $0.24. The market value of their outstanding shares is at $4.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
ALZNAlzamend Neuro Inc
$3.34-2.34%
Edge Rankings
Momentum
1.84
Price Trend
Short
Medium
Long
CLNNClene Inc
$3.50-10.1%
CLOVClover Health Investments Corp
$3.00-0.33%
ENSCEnsysce Biosciences Inc
$2.12-1.85%
HSDTHelius Medical Technologies Inc
$8.653.12%
PBMPsyence Biomedical Ltd
$5.05-3.44%
PRTGPortage Biotech Inc
$5.82-1.85%
SNESSenesTech Inc
$4.61-1.32%
TLPHTalphera Inc
$0.4066-5.44%
TRVNTrevena Inc
$0.9100-%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.